Welcome to our dedicated page for NextTrip news (Ticker: NTRP), a resource for investors and traders seeking the latest updates and insights on NextTrip stock.
NextTrip, Inc. reports developments in its travel-and-media business, which connects destination content with booking and fulfillment. The company’s platform includes JOURNY.tv, TravelMagazine.com, Five Star Alliance, the NXT2.0 booking and payments engine, and TA Pipeline for group travel and meetings.
Recurring news covers JOURNY programming and distribution, content-to-commerce tools, travel advisor and destination partnerships, premium wellness and destination-wedding offerings, and the integration of GoUSA TV content and distribution assets. Updates also address technology layers such as Agentic AI, interactive overlays, dynamic packaging, tokenized rewards, executive appointments, and financial results.
Neurotrope (Nasdaq: NTRP) has initiated a long-term Phase 2 clinical study of Bryostatin-1 for Alzheimer's disease, dosing its first patient. Supported by a $2.7 million NIH grant, this study aims to enroll about 100 patients over six months, evaluating cognitive benefits in the absence of Namenda. Previous pilot trials indicated Bryostatin-1 was well tolerated and showed promising cognitive improvements. The trial represents a key milestone for Neurotrope as it seeks to advance treatment options for Alzheimer's while planning a merger with Metuchen Pharmaceuticals.
Neurotrope has amended its merger agreement with Metuchen Pharmaceuticals, increasing Neurotrope stockholders' ownership in the new company, Petros Pharmaceuticals, to 49%. Originally, it was set at 22.5%. The merger will spin out Neurotrope's lead asset, Bryostatin-1, into a separate entity while Petros focuses on its core products: Stendra® and H-100, a treatment for Peyronie's disease. Petros aims to enhance Stendra's market presence and explore converting it to over-the-counter availability. The transaction is expected to close in the fourth quarter of 2020.
Neurotrope, Inc. (Nasdaq: NTRP) has secured a services agreement with Worldwide Clinical Trials to boost site recruitment for its Phase 2 clinical study of bryostatin-1 aimed at treating moderately severe Alzheimer's disease. Funded by a $2.7 million NIH grant, the study plans to enroll approximately 100 patients over a 6-month period, focusing on cognitive benefits using the Severe Impairment Battery score. The company anticipates dosing the first patient by late Q3 or early Q4 2020, following promising results from prior studies.